Chugai sales and marketing update

Chugai launched Zelboraf vemurafenib in Japan to treat unresectable melanoma with a BRAF mutation. The mutation is identified using the cobas 4800 BRAF V600 Mutation Test from Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland), which is the majority owner of Chugai. The National Health Insurance (NHI) reimbursement price for a 240 mg tablet is Y4,935.50 ($40.96). The usual dose is 960 mg twice daily. ...